Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy.

ABSTRACT: Cancer immunotherapy using monoclonal antibodies targeting immune checkpoints has undoubtedly revolutionized the cancer treatment landscape in the last decade. Immune checkpoint inhibitors can elicit long-lasting, previously unheard-of responses in a number of tumor entities. Yet, even in such tumors as metastatic melanoma and non-small cell-lung cancer, in which immune checkpoint inhibition has become the first-line treatment of choice, only a minority of patients will benefit considerably from these treatments. This has been attributed to a number of factors, including an immune-suppressive tumor microenvironment (TME). Using different modalities to break these barriers is of utmost importance to expand the population of patients that benefit from immune checkpoint inhibition. The multif

SUBMITTER: Tschernia NP 

PROVIDER: S-EPMC8986721 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature